An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia

Trial Identifier: ACE-WM-001
Sponsor: AcertaPharma
Start Date: September 2014
Primary Completion Date: October 2019
Study Completion Date: December 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
ES Salamanca, ES, 37007
FR Aurillac Cedex, FR, 15002
FR Clermond Ferrand, FR, 63003
FR Marseille CEDEX, FR, 13273
FR Montpellier, FR, 34295
FR Nantes, FR, 44093
FR Paris, FR, 75015
FR Paris cedex 13, FR, 75651
FR Pierre Benite Cedex, FR, 69495
FR Poitiers, FR, 86021
FR Reims Cedex, FR, 51092
FR Rennes Cedex, FR, 35000
FR Toulouse Cedex, FR, 31059
FR Vandoeuvre-les-Nancy, FR, 54500
GB Bournemouth, GB, BH7 7DW
GB Leeds, GB, LS9 7TF
GB Leicester, GB, LE1 7RH
GB London, GB, SW3 6JJ
GB London, GB, NW1 2BU
GB Oxford, GB, OX3 7LE
GB Plymouth, GB, PL6 8DH
GB Southampton, GB, SO16 6YD
GR Athens, GR, 11528
IT Bologna, IT, 40138
IT Milan, IT, 20162
IT Novara, IT, 28100
NL Amsterdam, NL, 1105AZ
NL Utrecht, NL, 2508GA
US, CA Santa Barbara, CA, US, 93105
US, CO Aurora, CO, US, 80012
US, DC Washington DC, DC, US, 20007
US, MN Minneapolis, MN, US, 55404
US, NY New York, NY, US, 10021
US, TN Nashville, TN, US, 37203
US, TX Austin, TX, US, 78705
US, TX Bedford, TX, US, 76022
US, TX Houston, TX, US, 77030
US, WA Vancouver, WA, US, 98684